Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HRTX
Strong SellSinkerHeron Therapeutics, Inc. · Healthcare · United States · $62M · Avg Vol: $846K/d
COMPANY DESCRIPTION
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing novel therapies for unmet medical needs in oncology and pain management. The company possesses a portfolio of commercialized products and a pipeline addressing significant market opportunities in supportive care and post-operative pain. Heron is known for its innovative drug delivery technologies, including long-acting formulations, designed to improve patient convenience and outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 107.7M | 127.0M | 144.3M | 154.9M | 12.9% | 151.2M | 148.2M | 145.9M | -3.0% |
| EPS | -2.24 | -1.67 | -0.80 | -0.09 | -0.12 | — | -0.19 | -0.13 | -0.11 | — |
| Shares | — | 119.2M | 150.3M | 152.1M | 188.3M | +58.0% | 189.9M | — | — | — |
| Debt | — | 157.5M | 179.6M | 177.8M | 140.6M | -3.7% | 148.4M | — | — | — |
| Equity | — | 13.6M | -34.0M | -33.7M | 14.3M | 1.8% | — | — | — | — |
| Op CF | — | -146.9M | -58.8M | -22.5M | -27.6M | — | -11.6M | — | — | — |
| Inv CF | — | -3.3M | 18.0M | 18.7M | 16.0M | — | — | — | — | — |
| Fin CF | — | 75.1M | 54.1M | 0.9M | 14.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HRTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HRTX | Heron Therapeutics, Inc.(you) | $62M | 7 | Strong Sell |
| KALA | KALA BIO, Inc. | $63M | 7 | Strong Sell |
| CNTX | Context Therapeutics Inc. | $56M | 6 | Strong Sell |
| CRDF | Cardiff Oncology, Inc. | $73M | 7 | Strong Sell |
| ATYR | aTyr Pharma, Inc. | $53M | 7 | Strong Sell |
| FLNA | Filana Therapeutics, Inc. | $58M | 4 | Strong Sell |
| TCRX | TScan Therapeutics, Inc. | $51M | 7 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%